361 related articles for article (PubMed ID: 25248874)
1. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.
Pei SN; Chen CH
Leuk Lymphoma; 2015 Jun; 56(6):1611-8. PubMed ID: 25248874
[TBL] [Abstract][Full Text] [Related]
2. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
7. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
8. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report.
Ciccullo A; Ponziani FR; Maiolo E; Pallavicini F; Pompili M
Infection; 2019 Apr; 47(2):313-316. PubMed ID: 30368733
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
Int J Hematol; 2009 Jul; 90(1):13-23. PubMed ID: 19544079
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
Mozessohn L; Chan KK; Feld JJ; Hicks LK
J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
[TBL] [Abstract][Full Text] [Related]
16. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
Kusumoto S; Tanaka Y; Ueda R; Mizokami M
J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
[TBL] [Abstract][Full Text] [Related]
18. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.
Lu S; Xu Y; Mu Q; Cao L; Chen J; Zhu Z; Lou Y; Meng H; Qian W; Tong H; Mai W; Huang J; Yu W; Zhao X; Jin J
Leuk Lymphoma; 2015 Apr; 56(4):1027-32. PubMed ID: 25065698
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
20. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Phipps C; Chen Y; Tan D
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):5-11. PubMed ID: 26705677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
